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Background. The renin-angiotensin-aldosterone system
(RAAS) contributes to hypertension and nephropathy. Until
recently, aldosterone either has not been considered or has been
considered a relatively minor component of the process—a con-
tribution that could be negated with angiotensin-converting en-
zyme (ACE) inhibition or angiotensin receptor blockade.
Methods. A Medline search was performed to identify rele-
vant literature describing the role of aldosterone in the patho-
genesis of renal dysfunction.
Results. Growing evidence from experimental and clinical
studies indicates that increased aldosterone is an independent
contributor to small- and medium-sized arterial injury and
nephropathy. Excess mineralocorticoid receptor stimulation of
local and systemic origin promotes target organ dysfunction,
vascular injury, and fibrosis, independent of the effects of other
elements of the RAAS. Blockade of the RAAS with ACE in-
hibition or angiotensin receptor blockade often does not con-
fer optimal protection from the effects of mineralocorticoids
on small- and medium-sized blood vessels. Recent preliminary
data from clinical studies indicate that aldosterone blockade
protects the kidneys, sharply decreases proteinuria, beyond the
activities of ACE inhibition or angiotensin receptor blockade
and independent of beneficial blood pressure effects, and can
protect patients from vascular injury associated with diabetes
mellitus and hypertension.
Conclusion. Aldosterone blockade with the selective aldos-
terone blocker eplerenone, in combination with other RAAS
inhibitors, is probably renoprotective and should be considered
as a component of the treatment regimens of diabetic and hy-
pertensive patients at risk for renal or cardiovascular disease
expression. A high priority should be placed on developing the
randomized, controlled trials required to establish that role.
The relationship between aldosterone and the evolu-
tion of renal disease has a curious history. There was much
research conducted between 1954 and 1964, followed by a
long, quiescent interval, which ended in 1996. In that year,
Greene, Kren, and Hostetter [1] started a second wave
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of research activity, which continues until this day. The
story begins with a description of aldosterone by Simp-
son, Tait, and Bush in 1952 [2]. In 1955, Dr. Jerome Conn
described the first patient with an aldosterone-secreting
tumor of the adrenal. He called it a case of aldosterone
excess due to an aldosterone-secreting tumor [3], a con-
dition that has since been termed Conn’s syndrome. That
patient was a middle-aged woman with an average blood
pressure of 180/110 mm Hg, severe hypokalemia, and pro-
teinuria. Given the level of blood pressure, the protein-
uria merited no comment.
By 1964, Conn was able to describe 145 proven cases,
including more than a dozen of his own [4]. The fact that
85% of these patients had gross proteinuria was of sub-
stantial interest. The possibility that the low serum potas-
sium concentration and potassium deficits contributed
to “kaliopenic nephropathy” was mentioned but did
not receive substantial attention. The possibility that al-
dosterone might directly damage the kidney was not
entertained.
In 1992, Weber and Brilla [5] described impressive evi-
dence to suggest that myocardial fibrosis, in at least some
models in which the renin-angiotensin system (RAS) was
activated, reflected a major contribution of the increase in
plasma aldosterone concentration. Within 2 years, Fuller-
ton and Funder [6] provided strong confirmation. At least
in part prompted by these observations, Greene, Dren,
and Hoestetter [1], in 1996, provided the first evidence
that aldosterone might be involved in the pathogenesis of
renal injury in a widely studied model of renal injury in
the rat, the remnant kidney model. In brief, they demon-
strated first that plasma aldosterone concentration was
markedly elevated in this model. They went on to show
that the angiotensin receptor blocker (ARB) losartan
and the angiotensin-converting enzyme (ACE) inhibitor
enalapril reduced renal injury. When rats received an al-
dosterone infusion to maintain very high plasma aldos-
terone levels; however, losartan and enalapril were not
effective in preventing or reversing renal injury. Taken
together, these data suggested strongly that aldosterone
was involved in the pathogenesis of renal injury.
Notably, in this study spironolactone administra-
tion did not reduce glomerulosclerosis, although it did
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transiently reduce proteinuria, arterial pressure, and car-
diac hypertrophy.
Rarely in the history of biology and medicine has a
laboratory experience been translated into therapeutic
studies more quickly and more effectively.
ANGIOTENSIN II AND ALDOSTERONE
IN BLOOD PRESSURE CONTROL
Angiotensin II
Angiotensin II (Ang II) is an octapeptide generated by
the action of ACE on the inactive precursor angiotensin
I. Ang II produces systemic vasoconstriction by binding
to type 1 angiotensin (AT1) receptors throughout the
body. In the kidney, this action appears to be, at least
in part, mediated through protein kinase C (PKC) ac-
tivation [7]. The process may be facilitated by an Ang
II−induced enhancement of noradrenergic neurotrans-
mission [8]. In addition, Ang II promotes salt and water
retention through two mechanisms: (1) direct stimulation
of sodium resorption in the proximal convoluted tubule
through endocrine, paracrine, and autocrine processes;
and (2) stimulation of aldosterone secretion [9, 10].
Aldosterone
Cells of the zona glomerulosa layer of the adrenal
cortex synthesize aldosterone. Although deoxycorti-
costerone, corticosterone, and cortisol all have min-
eralocorticoid properties, aldosterone is the principal
mineralocorticoid produced by the adrenal gland. A cru-
cial recent advance involves recognition that endothelial
and vascular smooth muscle cells (VSMCs) in the heart,
blood vessels, and brain also can synthesize aldosterone
[11–13]. Acting through epithelial mineralocorticoid re-
ceptors in the kidney, sweat glands, and colon and, to a
lesser extent, nonepithelial mineralocorticoid receptors
in the brain and cardiovascular system, aldosterone plays
a major role in salt and water homeostasis and potassium
excretion [14–16]. More recently, it has become apparent
that aldosterone also modulates the growth of fibroblasts
or myofibroblasts and, in association with transforming
growth factor b (TGF-b), helps regulate collagen depo-
sition in the heart and blood vessels [17–19].
RAAS inhibition and renal injury
Injury to the kidney mediated by the renin-
angiotensin-aldosterone system (RAAS) could occur
through multiple mechanisms. Impaired renal autoreg-
ulation could allow changes in systemic blood pressure
to be transmitted into the glomerulus and the peritubu-
lar capillaries [20]. This increased intraglomerular pres-
sure could produce injury with both glomerulosclerosis
and tubulointerstitial damage [21]. RAAS-mediated in-
jury also could develop through ischemia secondary to
hypertension-induced arteriolar sclerosis. Both preclini-
cal and clinical evidence indicate that interruption of the
RAAS ameliorates renal vascular remodeling and asso-
ciated injury in patients with hypertension.
The role of the RAAS in the development of renal
injury has been demonstrated repeatedly in preclinical
studies [22–25]. In stroke-prone spontaneously hyperten-
sive rats and other experimental models, ACE inhibitors
have been shown to block Ang II formation in the re-
nal vasculature, reduce arterial vasoconstriction, and de-
crease glomerular capillary pressure [22–25]. The effect is
at least partially independent of the blood-pressure low-
ering effects of these drugs.
The renoprotective effects of RAAS inhibition have
been confirmed unambiguously in humans. Randomized,
clinical trials of RAAS blockade in patients with renal
disease (with or without diabetes) indicate that ACE in-
hibitors and ARBs provide renal protection independent
of their effects on systemic blood pressure [26–33]. In
an analysis of 11 randomized controlled trials in patients
with nondiabetic renal disease, ACE inhibitors produced
a 31% decrease in the relative risk of developing end-
stage renal disease (ESRD) compared to regimens that
did not include ACE inhibitors [34]. Blockade of the
RAAS through the use of ARBs also has been shown
to be renoprotective in patients with type 2 diabetes.
Results from the Reduction in Endpoints in NIDDM
with the Angiotensin II Antagonist Losartan (RENNAL)
study, Irbesartan in Patients with Type 2 Diabetes and Mi-
croalbuminuria (IRMA) study, and Irbesartan Diabetic
Nephropathy Trial (IDNT) demonstrated that ARBs re-
duce the progression of renal disease [31–33]. The reno-
protection produced by ARBs was similar to that of ACE
inhibitors, suggesting that a common mechanism is in-
volved, but head-to-head trials are needed to confirm this
hypothesis.
ALDOSTERONE AND RAAS-INDUCED
VASCULAR INJURY AND NEPHROPATHY
Preclinical evidence strongly indicates that aldos-
terone, per se, is an essential link between hypertension
and the development of vascular remodeling and hyper-
tensive nephropathy. Clinical evidence is preliminary but
is strongly supportive.
Aldosterone in the remnant kidney model
Greene, Kren, and Hostetter [1] evaluated the inde-
pendent role of aldosterone in renal injury in the remnant
kidney model and focused on the response of aldosterone
to RAAS inhibition. In the initial stage of the experiment,
rats were divided into four groups: (1) sham-operated
rats, (2) untreated remnant kidney rats (REM), (3) REM
rats treated with losartan and enalapril (REM Ang II
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antagonists), and (4) REM Ang II antagonist rats in-
fused with exogenous aldosterone (REM Ang II antag-
onist + aldo). Aldosterone was infused continuously in
the last group to maintain aldosterone levels compara-
ble with those in untreated REM rats. Activation of the
aldosterone component of the RAAS in REM rats was
indicated by their larger adrenal glands plus >tenfold
elevation in plasma aldosterone compared with animals
in the sham group. Rats with remnant kidneys treated
with an ARB and an ACE inhibitor demonstrated signif-
icant suppression of hyperaldosteronism plus significant
attenuation of proteinuria, hypertension, and glomeru-
losclerosis compared with untreated REM animals.
Infusion of aldosterone into REM Ang II antagonist an-
imals increased proteinuria, hypertension, and glomeru-
losclerosis compared with REM Ang II antagonist rats
that did not receive exogenous aldosterone. The impor-
tance of aldosterone in this model is reflected in the re-
versal of the protective effects of treatment with losartan
and enalapril; after 4 weeks, the physiologic and morpho-
logic changes in the REM Ang II antagonist group that
also received exogenous aldosterone were identical to the
changes in untreated REM animals.
Approaching the issue from a different perspective,
Quan, Walser, and Hill [35] evaluated the independent ef-
fects of aldosterone and dietary protein intake. Partially
nephrectomized rats underwent adrenalectomy followed
by either low- or high-dose corticosterone replacement
therapy. All animals were provided a choice of water or
saline to drink. Proteinuria was significantly increased
by the presence of intact adrenal glands, higher corti-
costerone maintenance level, and higher dietary protein.
Because the animals had access to both salt and water
ad libitum, the extracellular fluid volume was identical in
the groups. Both adrenalectomy and protein restriction
improved renal histopathology scores. The final glomeru-
lar filtration rate (GFR) was significantly improved by
adrenalectomy when nonsurvivors were scored as hav-
ing zero clearance, but not if the analysis was limited
to survivors. The GFR was not affected by diet or by
corticosterone level. The investigators concluded that re-
moval of the source of endogenous mineralocorticoids
with adrenalectomy could ameliorate the effects of re-
nal ablation, whereas corticosterone replacement only
altered the degree of proteinuria.
Aldosterone in spontaneously hypertensive rats
Horiuchi et al [36] investigated the role of aldos-
terone in the stroke-prone spontaneously hypertensive
rat model by comparing the characteristics of the strain’s
cytosolic mineralocorticoid receptors with those of nor-
motensive Wistar-Kyoto rats. By 6 weeks of age, the
animals were hypertensive, exhibited an increased con-
centration of renal cytosolic aldosterone receptors, and
showed decreases in urine sodium and volume. Plasma
aldosterone levels, however, were similar to those of
the normotensive Wista-Kyoto rats. By 10 weeks of age,
plasma aldosterone concentrations became significantly
higher than those in the Wistar-Kyoto animals. Notably,
although the concentration of the mineralocorticoid re-
ceptor was elevated in the stroke-prone spontaneously
hypertensive animals, the receptors’ molecular proper-
ties did not differ from those of the controls. These data
suggest that an elevated concentration of aldosterone re-
ceptors in these animals may be a significant factor in their
predisposition to hypertension and its associated vascular
injury.
To evaluate the role of mineralocorticoid receptor
blockade in the progression of vascular injury in saline-
drinking stroke-prone spontaneously hypertensive rats,
Rocha et al [37] implanted time-release pellets contain-
ing 200 mg of spironolactone. Spironolactone treatment
significantly decreased proteinuria (P < 0.0001). The
blockade of mineralocorticoid receptors also significantly
increased survival. Although both the control and the
spironolactone-treated populations were severely hyper-
tensive, all but one of the control rats had evidence
of stroke and died by 16 weeks of age; conversely, the
spironolactone-treated animals remained asymptomatic
through 19 weeks (P < 0.03). In addition urinary protein
excretion did not increase from baseline levels during
spironolactone treatment, whereas urinary protein lev-
els were significantly elevated in controls (P < 0.0001)
(Fig. 1). Microscopic examination demonstrated that
spironolactone protected the animals from the develop-
ment of malignant nephrosclerotic and cerebrovascular
lesions. Compared with controls, mineralocorticoid re-
ceptor blockade produced no differences in systolic blood
pressure or excretion of water or electrolytes.
To evaluate the role of the various elements of the
RAAS, the development of hypertension-associated vas-
cular lesions was further evaluated in this model. Rocha
et al [38] studied the effects of chronic aldosterone
infusion on vascular lesions in animals treated with cap-
topril. Animals were divided into four groups: (1) ve-
hicle alone, (2) captopril alone, (3) aldosterone alone,
and (4) combined dosing with captopril plus aldosterone
at two different dose levels. All animals had signifi-
cantly elevated blood pressure. Animals treated with
either vehicle or aldosterone alone developed severe
proteinuria and had arteriolar and glomerular throm-
botic and proliferative lesions (Fig. 2). Animals treated
with captopril alone had reduced levels of plasma aldos-
terone, failed to develop histologic lesions of malignant
nephrosclerosis, and had marked reductions in the degree
of proteinuria. However, despite concomitant ACE inhi-
bition, the aldosterone-treated subgroup developed his-
tologic and clinical characteristics comparable with those
seen in the vehicle- and aldosterone-only stroke-prone
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Fig. 1. Effect of spironolactone on urinary protein excretion in stroke-
prone spontaneously hypertensive rats. Line graphs showing (A) sys-
tolic arterial blood pressure (SBP) and (B) urinary protein excretion
(UPE) in stroke-prone spontaneously hypertensive rats into which
time-release pellets containing spironolactone or placebo were im-
planted. Values are mean ± SEM. Numbers in parenthesis indicate
the number of animals. ∗P < 0.001 compared with placebo-implanted
controls. Reprinted with permission from Rocha et al [38].
spontaneously hypertensive subgroups. In this model,
there is a clear role for aldosterone in the pathogene-
sis of vascular injury, and aldosterone-related injury is
independent of the effects on blood pressure.
Aldosterone in the L-NAME model
In a follow-up study, Rocha et al [39] examined the
role of aldosterone in the development of renal injury
and myocardial necrosis in another rat model. Hyperten-
sion was induced in male Wistar rats by a combination
of sustained infusion of Ang II, infusion of an inhibitor
of nitric oxide synthase, Nx-nitro-L-arginine methyl es-
ter (L-NAME), and a high-sodium diet. In this model,
the hypertensive animals developed fibrinoid necrosis of
the renal arterioles and proteinuria plus biventricular my-
ocardial hypertrophy and necrosis. To evaluate the role
of aldosterone in mediating the cardiovascular changes,
they performed an ablation/replacement experiment.
Adrenalectomy or aldosterone blockade with adminis-
tration of the selective aldosterone blocker eplerenone
markedly reduced the cardiac and renal damage without
significantly altering blood pressure. When adrenalec-
tomized, glucocorticoid-replaced, L-NAME/Ang II/salt-
Fig. 2. Vascular pathology of malignant nephrosclerosis in saline-fed
stroke-prone spontaneously hypertensive rats. Representative pho-
tomicrograph of renal cortex from saline-drinking stroke-prone spon-
taneously hypertensive after 2 weeks of treatment with vehicle or
aldosterone. Typical lesions of malignant nephrosclerosis consist of is-
chemic or thrombotic glomeruli (large arrows), extensive mural fib-
rinoid deposits in microvessels (large arrowheads), and fragmented
extravasated erythrocytes (small arrowheads). Reprinted with permis-
sion from Rocha et al [38].
treated animals were then infused with aldosterone, the
cardiovascular damage was restored. This study provides
further strong support for the independent role of miner-
alocorticoids in the genesis of hypertensive nephropathy
and vascular injury.
ALDOSTERONE AND RENAL REMODELING
The vasculature is an integrated organ composed of
endothelial cells, smooth muscle fibers, fibroblasts, and
connective tissue. These elements are capable of identi-
fying changes within their milieu and responding in an
attempt to reestablish homeostasis. Vascular remodeling
is an active process resulting in alterations in the growth,
apoptosis, cell migration, and extracellular matrix due
to an altered expression of growth factors, vasoactive
substances, and mechanical factors [40]. Acting through
autocrine, paracrine, and endocrine pathways, aldos-
terone is increasingly being recognized as an important
contributor.
The primary role of mineralocorticoid receptors
Mineralocorticoid receptors are present in vascular
smooth muscle and endothelial cells [41]. The initial step
in mineralocorticoid-induced vascular remodeling results
from events triggered when aldosterone or other miner-
alocorticoids bind to mineralocorticoid receptors on vas-
cular cells. Gavras et al [42] used the well-established
deoxycorticosterone acetate (DOCA) model to address
the association of mineralocorticoid receptor activation
and vascular response. In this model, hypertension is in-
duced in uninephrectomized rats using DOCA and high
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Table 1. Possible pathways of mineralocorticoid-induced
vasculopathy
Plasminogen activator inhibitor-1 (PAI-1)
Transforming growth factor-b (TGF-b1)
Generation of reactive oxygen species
Endothelial dysfunction
Up-regulated expression of angiotensin type 1 receptor (AT1R)
Changes in vascular smooth muscle morphology and physiology
salt intake. After a period of 3 to 4 weeks of positive
sodium balance and rising blood pressure, a malignant
phase developed that was marked by fibrinoid necrosis
of renal arterioles. The cascade of events leading to the
fibrinoid necrosis of the renal arterioles was clearly miner-
alocorticoid dependent. Wistar-Furth rats are resistant to
the hypertensive effects of DOCA [43], reflecting a par-
tial defect of mineralocorticoid responsivity in vascular
smooth muscle and possibly the kidney. Ullian et al [43]
demonstrated that aldosterone treatment of VSMCs cul-
tured from these rats produced less smooth muscle con-
traction and regulation of angiotensin metabolism than
in control wild-type Wistar rats.
PATHOLOGIC PROCESSES IMPLICATED IN
ALDOSTERONE-INDUCED RENAL VASCULAR
REMODELING
In addition to its classical effects on sodium and
potassium transport in the renal tubule, newly emerg-
ing data are revealing a number of pathologic processes
by which aldosterone mediates renal vascular remodel-
ing (Table 1). Although the molecular pathways of these
processes have not been clearly elucidated, they all ap-
pear to contribute to the final common pathway of
aldosterone-mediated renal vascular remodeling.
Plasminogen activator inhibitor-1
Increased levels of plasminogen activator inhibitor-1
(PAI-1), the primary inhibitor of the fibrinolytic sys-
tem, appear to contribute significantly to aldosterone-
mediated injury and fibrosis [44]. In addition to its
primary effects on the interactions between tissue plas-
minogen activator, urokinase, and plasminogen, PAI-1
also modulates extracellular matrix turnover and activa-
tion of latent growth factors. Increased levels of PAI-1
have been identified as a risk factor for coronary heart
disease and are thought to contribute to the microcir-
culatory abnormalities of other diseases [45]. Increased
levels of PAI-1 also are centrally involved in the patho-
genesis of both glomerulosclerosis and tubulointerstitial
fibrosis [46]. By interacting with Ang II, aldosterone in-
creases PAI-1 expression in tissue cultures of endothelial
cells as well as in vivo. This promotes the accumulation of
extracellular matrix in blood vessels, glomeruli, and the
heart.
There is a direct functional link between the RAAS,
aldosterone, and the human fibrinolytic system. Levels
of PAI-1 correlate significantly with aldosterone concen-
tration during periods of low salt intake [47]. Whereas
both Ang II and aldosterone modulate PAI-1 expression,
substantial evidence supports the role of aldosterone as a
contributor to Ang II effects on fibrinolysis [48]. In a rat
model, radiation to the kidneys was followed by an eight-
fold increase in the expression of PAI-1 mRNA (P <
0.001) [44]. Blockade of the RAAS with an ARB or
aldosterone blockade with spironolactone significantly
decreased the development of glomerulosclerosis and as-
sociated proteinuria. The renoprotective effects of min-
eralocorticoid receptor blockade may reflect, at least in
part, down-regulation of PAI-1 expression.
TGF-b
TGF-b is a cytokine that promotes fibroblast differ-
entiation and proliferation, up-regulates collagen syn-
thesis and deposition, and down-regulates the release of
the matrix metalloproteinase collagenase [49]. Following
blood vessel injury, Ang II generated at the damaged site
stimulates synthesis of TGF-b1. Uninephrectomized rats
treated with aldosterone demonstrate increased binding
density of ACE and Ang II receptors, increased expres-
sion of TGF-b1 and collagen mRNAs, and diffuse re-
nal medullary and cortical fibrosis accompanied by the
accumulation of abundant myofibroblasts at the sites
of fibrosis [49]. Infusion of aldosterone induced these
changes in the presence of AT1 receptor blockade with
losartan, suggesting that aldosterone has an independent
role in nephrosclerosis/glomerulosclerosis and RAAS-
related TGF-b1 release.
Reactive oxygen species
Superoxide anion, hydroxyl radicals, and hydrogen per-
oxide are reactive oxygen species that are produced in
a number of disease states and have been implicated
in a number of disease processes [50]. They damage
cells by peroxidation of the cell membrane lipids and
by denaturing proteins. In an experimental stroke-prone
spontaneously hypertensive rat model [abstract P4.03;
Stier C, Jr., et al, Proc Int Soc Hypertens, August 23,
2000, Chicago, IL, USA], the RAAS was blocked by
lisinopril, and aldosterone was infused following ACE
inhibition. Infusion of aldosterone resulted in the devel-
opment of renal vascular injury with thrombotic microan-
giopathy, tubular ischemia, and proteinuria. Because
administration of scavengers of reactive oxygen species
decreased kidney damage in this model, a component
of mineralocorticoid-induced injury may have resulted
from the generation of oxygen-free radicals and hydrogen
peroxide.
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Endothelial dysfunction
Nitric oxide of endothelial origin is a potent endoge-
nous vasodilator. Although nitric oxide has several fea-
tures, significant properties relevant to this discussion
include the ability of nitric oxide to influence renal hemo-
dynamics and tubuloglomerular feedback, inhibit ma-
trix protein accumulation, and block the proliferation
of smooth muscle cells and fibroblasts [51]. Sustained
inhibition of nitric oxide synthase (NOS) can produce
hypertension and vascular injury. In tissue culture, aldos-
terone decreases interleukin (IL)-1b−stimulated nitric
oxide bioactivity [52].
Dysfunctional endothelial cells exhibit impaired nitric
oxide–induced vasodilation. Endothelial dysfunction is a
sign of a vascular injury and marks patients at risk for
cardiovascular adverse events [53]. It has been shown
that aldosterone induces endothelial dysfunction in nor-
mal people. In a trial of 16 healthy volunteers [54], al-
dosterone infusion attenuated endothelium-dependent
vasodilatation to acetylcholine compared with ei-
ther prednisolone or placebo, whereas endothelium-
independent vasodilatation was not affected by either
hormone. Further, in patients with chronic heart failure,
mineralocorticoid receptor blockade with spironolactone
increased nitric oxide bioactivity, improved endothelial
vasodilatory dysfunction, and suppressed the conversion
of vascular ATI to Ang II [55]. Endothelial dysfunction
appears to be one of the mechanisms involved in the de-
velopment of microalbuminuria through alterations in
the permselectivity of the glomerular basement mem-
brane [56].
The relative contributions of aldosterone and gluco-
corticoid binding to mineralocorticoid receptors in en-
dothelial dysfunction is an interesting question. Because
mineralocorticoid receptors have similar affinities for
corticosterone, cortisone, and aldosterone—and circu-
lating levels of these glucocorticoids are in great excess
of plasma aldosterone levels—aldosterone must bind to
mineralocorticoid receptors against stoichiometric odds.
One strategy used in vascular tissues to regulate cellular
glucocorticoid concentrations is through the activity of
11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2).
This enzyme inactivates glucocorticoids, thereby increas-
ing the probability of aldosterone binding to mineralo-
corticoid receptors [57, 58].
In the absence of the enzyme, the relative excess of
glucocorticoids to mineralocorticoids can produce hyper-
tension. Glycyrrhizic acid (GA), found in liquorice, is a
potent inhibitor of 11b-HSD2. In a rat model of GA-
induced hypertension, mineralocorticoid receptor antag-
onism with spironolactone prevented upregulation of
endothelin-1, a potent vasoconstrictor; completely re-
stored nitric oxide–mediated endothelial function; and
normalized blood pressure [59].
Alterations in VSMCs
Aldosterone has multiple actions at the level of
VSMCs. These effects can lead to hypertension and in-
creased vasoreactivity and peripheral vascular resistance.
For example, aldosterone may potentiate the pressor re-
sponses to Ang II by significantly up-regulating the num-
ber of Ang II receptors and releasing intracellular cal-
cium stores [60]. Aldosterone also directly influences the
movement of sodium ions across the VSMC membrane
by up-regulating the synthesis of sodium channels, which
may contribute to vascular hyperreactivity in disorders of
mineralocorticoid excess [61]. Aldosterone also inhibits
the uptake of norepinephrine by VSMCs. In combina-
tion with the aldosterone-mediated decrease in cardiac
myocyte norepinephrine uptake, this has the potential
to lead to ventricular arrhythmias. Mineralocorticoid re-
ceptor blockade with spironolactone can normalize this
dysfunction [62]. Aldosterone also significantly enhances
the Ang II−induced increase in [3H]leucine incorpora-
tion in smooth muscle cells; this process is inhibited by
ZK 91587, a type 1 mineralocorticoid receptor antagonist
[63]. These metabolic effects indicate that aldosterone
may directly participate in the hypertrophy and dysfunc-
tion of VSMCs.
ALDOSTERONE BLOCKADE AND
PREVENTION OF RAAS-INDUCED
NEPHROPATHY
Evidence from various rat models reviewed above in-
dicates that aldosterone plays a major role in sustaining
hypertension and promoting fibroproliferation and de-
struction of the kidneys. As in animal studies, elevated
levels of aldosterone occur in patients with chronic renal
disease and appear to be independent of plasma potas-
sium concentration and plasma renin activity (PRA).
In a study of 28 patients with varying degrees of renal
dysfunction and comparable serum potassium and PRA
levels, plasma aldosterone generally was elevated when
creatinine clearance was lower than 50% of normal [64].
The relationship of primary aldosteronism, renal in-
jury, and cardiovascular risk also has been evaluated.
During the decade after he first reported a case of a pa-
tient with an aldosterone-secreting adrenal tumor, Conn,
Knopf, and Nesbit [4] found that 85% of patients with
primary aldosteronism also have proteinuria, a signifi-
cant risk factor for cardiovascular events. It is not sur-
prising that a Japanese study recently reported that in
a group of 58 patients with an adrenal cortical adenoma
and primary aldosteronism, cardiovascular complications
were identified in 34% [65]. The most common indicator
of mineralocorticoid-induced vasculopathy was protein-
uria, identified in 24% of patients. In male patients older
than 40 years of age, proteinuria was significantly asso-
ciated with the occurrence of stroke (P = 0.03). These
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findings provide further evidence that the aldosterone-
induced renal vascular injury is indicative of pathology in
other vascular beds.
Does mineralocorticoid receptor antagonism have
clinical benefits? Until recently, spironolactone, a non-
specific aldosterone receptor blocker, was the only agent
of this class clinically available. Preliminary data indicate
that spironolactone decreases proteinuria in patients with
both chronic renal disease [66] and those with type 2 di-
abetes and early nephropathy [67]. The use of spirono-
lactone is limited by the prevalence of adverse sexual
effects. The increased selectivity of eplerenone, recently
approved for use by the federal Food and Drug Adminis-
tration, allows for clinical efficacy without the unwanted
side effects [68].
Data regarding eplerenone safety and efficacy are be-
ginning to emerge with three studies recently presented.
However, the results have only been reported in ab-
stract form and renal effects were not primary end points
in two of these studies. Epstein et al [abstract; Epstein
M, et al, J Am Coll Cardiol 39:Suppl A, 2002] evalu-
ated eplerenone, enalapril, and a combination of both
agents in 266 patients with type 2 diabetes mellitus,
mild-to-moderate hypertension, and proteinuria [urinary
albumin:creatinine ratio (UACR) ≥100 mg/g] during
a 24-week, double-blind study. Eplerenone decreased
microalbuminuria independent of its antihypertensive
activity. Compared with enalapril, the renoprotective
properties of eplerenone were significantly better by
week 24. UACR was reduced by 62% (95% CI, 53%–
69%) in the eplerenone group and by 45% (95% CI,
32%–55%) in the enalapril group (P = 0.015 between
groups). However, the reduction in albumin excretion
with combination therapy was significantly more effective
than monotherapy with either drug. UACR was reduced
by 74% (95% CI, 67%–79%) in the eplerenone/enalapril
group (P = 0.018 vs. eplerenone; P < 0.001 vs. enalapril)
(Fig. 3). Elevated potassium levels (≥6 mEq/L) were ob-
served in eight eplerenone patients, two enalapril, and
eight eplerenone/enalapril patients. More patients were
withdrawn for hyperkalemia in the eplerenone/enalapril
group (N = 14) than in the eplerenone group (N = 6)
or the enalapril group (N = 2). A subsequent follow-up
study is being conducted to determine if lower doses of
eplerenone will maintain reductions in albumin excretion
without substantially increasing potassium levels.
In another study, Burgess et al [abstract; Burgess E,
et al, Am J Hypertens 15:23A, 2002] compared antihyper-
tensive efficacy and safety of eplerenone and enalapril
in the treatment of patients with mild-to-moderate hy-
pertension. Among the subset of patients (number of
patients not stated) with microalbuminuria at baseline
(UACR ≥30 mg/g), the mean percent reduction in albu-
min excretion achieved by eplerenone was significantly
superior to that of enalapril (61.5% vs. 25.7%; P =
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P = 0.018
Fig. 3. Percent change in urinary albumin:creatinine ratio at week 24
in eplerenone, enalapril, and eplerenone/enalapril patients. ∗P < 0.001
week 24 vs. baseline for all treatments [abstract; Epstein M, et al, J Am
Coll Cardiol 39:Suppl A, 2002].
0.01) and was independent of blood pressure reduc-
tion. Another abstract has suggested that eplerenone and
enalapril reduce UACR from baseline values and that
the combination of the two drugs produces additive ben-
efit among patients with hypertension and left ventricu-
lar hypertrophy [abstract; Pitt B, et al, Am J Hypertens
2002:15:23A-24A, 2002]. However, this preliminary re-
port is not sufficiently detailed to make a proper inter-
pretation.
CONCLUSION
A growing body of preclinical and clinical evidence
supports the role of aldosterone as an independent and
powerful mediator of renal vascular remodeling and
in the progression of both hypertensive renal vascu-
lar disease and diabetic nephropathy. Although multiple
aldosterone-mediated mechanisms appear to contribute
to renal vascular injury, a specific, final, common pathway
is yet to be clearly defined.
Whereas aldosterone blockade with spironolactone as
a therapeutic option has been limited by its lack of
specificity, clinical and experimental evidence indicate
that aldosterone antagonism can protect the kidneys and
decrease proteinuria, a surrogate marker of renal injury
and cardiovascular risk. Use of eplerenone—alone or
in combination with other inhibitors of elements of the
RAAS—can decrease the incidence of adverse events as-
sociated with nonselective aldosterone blockade, provide
effective blood pressure control, and increase efficacy in
combination therapy. Clearly, enough has been learned
to justify, indeed mandate, the clinical trial necessary to
prove the therapeutic efficacy.
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